3 hot healthcare stocks to buy in weakness

Co-founder of the Switzer Report
Print This Post A A A

Key points

  • Ramsay might be fully priced but it is a company that has consistently met or exceeded its forecasts.
  • CSL recently completed the acquisition of Novartis’ influenza vaccine business, making CSL the second largest influenza vaccine manufacturer in the world.
  • Resmed’s FY15 revenue was US$1.7 billion, up 13% on a constant currency basis. It’s a little more speculative, but worth the risk.

The healthcare sector has been the best performing sector on the ASX over the last decade. To the end of August, it’s up 15.1% pa compared to an average of 6.2% pa for the S&P/ASX 200 – or a massive outperformance of almost 9% per annum. The same is true over 5 years, 3 years, 1 year – and even this calendar year, where the S&P/ASX 200 (as measured by the accumulation index) is down 0.85% to last Friday, while healthcare is up by 4.96%.

Total Returns

20150921 - healthcare returns

Also from this edition